Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis
暂无分享,去创建一个
Mitchell R. McGill | J. Dranoff | Stefanie Kennon-McGill | E. Peterson | H. Spencer | S. McCullough | J. Moran | L. James | Joel H. Vazquez | S. Mathews | Morgan E Tripod | Davis P Fleming
[1] Mitchell R. McGill,et al. Biomarkers of mitotoxicity after acute liver injury: Further insights into the interpretation of glutamate dehydrogenase , 2021, Journal of clinical and translational research.
[2] H. Jaeschke,et al. Impaired protein adduct removal following repeat administration of subtoxic doses of acetaminophen enhances liver injury in fed mice , 2021, Archives of Toxicology.
[3] J. Dear,et al. MicroRNA‐122 and cytokeratin‐18 have potential as a biomarkers of drug‐induced liver injury in European and African patients on treatment for mycobacterial infection , 2021, British journal of clinical pharmacology.
[4] Mitchell R. McGill,et al. The development and hepatotoxicity of acetaminophen: reviewing over a century of progress , 2020, Drug metabolism reviews.
[5] T. H. Nguyen,et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The lancet. Gastroenterology & hepatology.
[6] Shari S. Rogal,et al. Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis , 2020, Alimentary pharmacology & therapeutics.
[7] E. Tapper,et al. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[8] A. Lok,et al. Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis , 2019, Hepatology communications.
[9] William M. Lee,et al. Acute liver failure , 2019, The Lancet.
[10] I. Higginson,et al. Symptom prevalence and quality of life of patients with end-stage liver disease: A systematic review and meta-analysis , 2018, Palliative medicine.
[11] Anne E Schweighardt,et al. A Systematic Review of the Evidence Behind Use of Reduced Doses of Acetaminophen in Chronic Liver Disease , 2018, Journal of pain & palliative care pharmacotherapy.
[12] William M. Lee,et al. Acute Liver Failure of Indeterminate Etiology: A Comprehensive Systematic Approach by An Expert Committee to Establish Causality , 2018, The American Journal of Gastroenterology.
[13] M. Rakoski,et al. Pain management in patients with cirrhosis , 2018, Clinical liver disease.
[14] K. Heard,et al. Serum paracetamol-protein adducts in ambulatory subjects: Relationship to recent reported paracetamol use , 2017, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[15] M. Pirmohamed,et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies , 2017, The lancet. Gastroenterology & hepatology.
[16] Mitchell R. McGill,et al. Removal of acetaminophen protein adducts by autophagy protects against acetaminophen-induced liver injury in mice. , 2016, Journal of hepatology.
[17] K. Heard,et al. Paracetamol (acetaminophen) protein adduct concentrations during therapeutic dosing. , 2016, British journal of clinical pharmacology.
[18] M. Slawson,et al. Prolonged Acetaminophen-Protein Adduct Elimination During Renal Failure, Lack of Adduct Removal by Hemodiafiltration, and Urinary Adduct Concentrations After Acetaminophen Overdose , 2014, Journal of Medical Toxicology.
[19] S. Alavian,et al. The Therapeutic Use of Analgesics in Patients With Liver Cirrhosis: A Literature Review and Evidence-Based Recommendations , 2014, Hepatitis monthly.
[20] A. Nicoll,et al. Analgesia for the cirrhotic patient: A literature review and recommendations , 2014, Journal of gastroenterology and hepatology.
[21] Dean P. Jones,et al. Age-related alterations of plasma glutathione and oxidation of redox potentials in chimpanzee (Pan troglodytes) and rhesus monkey (Macaca mulatta) , 2014, AGE.
[22] Shari S. Rogal,et al. Pain and Opioid Use in Chronic Liver Disease , 2013, Digestive Diseases and Sciences.
[23] J. Vergniol,et al. Non‐invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[24] M. Lai,et al. Non‐steroidal anti‐inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[25] Hartmut Jaeschke,et al. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. , 2012, The Journal of clinical investigation.
[26] I. Papet,et al. Acetaminophen Metabolism After Major Surgery: A Greater Challenge With Increasing Age , 2011, Clinical pharmacology and therapeutics.
[27] V. de Lédinghen,et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. , 2010, Ultrasound in medicine & biology.
[28] N. Chandok,et al. Pain management in the cirrhotic patient: the clinical challenge. , 2010, Mayo Clinic proceedings.
[29] P. Hauser,et al. Pain, substance use disorders and opioid analgesic prescription patterns in veterans with hepatitis C. , 2008, Journal of pain and symptom management.
[30] V. Navarro,et al. Use of Over-the-Counter Analgesics in Patients with Chronic Liver Disease , 2008, Drug safety.
[31] S. Lorenzini,et al. Age-related influence on thiol, disulfide, and protein-mixed disulfide levels in human plasma. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.
[32] Neil Kaplowitz,et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. , 2006, JAMA.
[33] S. Sudan,et al. The pharmacokinetics of a single rectal dose of paracetamol (40 mg·kg−1) in children with liver disease , 2006, Paediatric anaesthesia.
[34] V. de Lédinghen,et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study , 2005, Gut.
[35] K. Tolman,et al. The Therapeutic Use of Acetaminophen in Patients with Liver Disease , 2005, American journal of therapeutics.
[36] P. Zapater,et al. Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status , 2004, Alimentary pharmacology & therapeutics.
[37] N. Finlayson,et al. Paracetamol metabolism in chronic liver disease , 1979, European Journal of Clinical Pharmacology.
[38] J. Miners,et al. Comparison of paracetamol metabolism in young adult and elderly males , 2004, European Journal of Clinical Pharmacology.
[39] Subir Ghosh,et al. Nonparametric Analysis of Longitudinal Data in Factorial Experiments , 2003, Technometrics.
[40] K. Muldrew,et al. Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high-performance liquid chromatography with electrochemical detection. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[41] Dean P. Jones,et al. Redox state of glutathione in human plasma. , 2000, Free radical biology & medicine.
[42] T. Murakami,et al. Acetaminophen plasma level after oral administration in liver cirrhotic patients suffering from schistosomal infection. , 1996, International journal of clinical pharmacology and therapeutics.
[43] V. de Lédinghen,et al. Non-steroidal anti-inflammatory drugs and variceal bleeding: a case-control study. , 1996, Journal of hepatology.
[44] K. Byth,et al. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease , 1995, Hepatology.
[45] N. Leung,et al. Increased oxidative metabolism of paracetamol in patients with hepatocellular carcinoma. , 1991, Cancer letters.
[46] G. Benson. Acetaminophen in chronic liver disease , 1983, Clinical pharmacology and therapeutics.
[47] P. B. Andreasen,et al. Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. , 2009, Acta medica Scandinavica. Supplementum.
[48] R. Olsson,et al. Elimination of paracetamol in chronic liver disease. , 1978, Acta hepato-gastroenterologica.
[49] N. Finlayson,et al. Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease. , 1977, British medical journal.
[50] N. Finlayson,et al. Proceedings: Antipyrine, lingocaine and paracetamol metabolism in chronic liver disease. , 1975, Gut.
[51] B B Brodie,et al. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. , 1973, The Journal of pharmacology and experimental therapeutics.
[52] J. Fevery,et al. Conjugation of N-acetyl-p-aminophenol (N.A.P.A.) in adult liver patients. , 1969, Acta hepato-splenologica.